Infectious Disease Update: This Week's Top 5 Stories
With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.
Most weeks don't have major breakthroughs, studies, and approvals across the spectrum of infectious diseases. This week was an exception.
Watch and read all about the most significant news of the past week with Contagion's Infectious Disease Update.
FDA Approves First-Ever Fecal Microbiota, RBX2660, for C Difficile Recurrence
On Wednesday, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product. The treatment is indicated to prevent recurrent C difficile infection in adults.
Considering Criteria for Admission for Skin and Soft Tissue Infections
In episode 1 of this short video series, infectious diseases clinical pharmacy specialist Bruce M. Jones, PharmD, FIDSA, BCPS, the patients best suited for inpatient versus outpatient care for these infections.
Experimental HIV Vaccine Elicits Broadly Neutralizing Antibodies
A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.
FDA Expands Ibrexafungerp Approval for Reduction of Recurrent Yeast Infection
Ibrexafungerp tablets (Brexafemme) were already FDA approved to treat vulvovaginal candidiasis (VVC) and have now received a second indication for the reduction of recurrent VVC (yeast infection).
Type I Interferon Response Linked to Resistance to HCV Infection
Resistance to hepatitis C infection may be much greater than previously thought, according to new research by investigators at Trinity College Dublin that revealed associated biological factors.
